tiprankstipranks
Tvardi Therapeutics (TVRD)
NASDAQ:TVRD
US Market
TVRD
Tvardi Therapeutics
RESEARCH TOOLSreports
Want to see TVRD full AI Analyst Report?

Tvardi Therapeutics (TVRD) Stock News & Sentiment

2,520 Followers
Buy Rating on Tvardi: Differentiated STAT3 Platform, Upcoming TTI-109/TTI-101 Catalysts, and Attractive Risk‑Reward Through 2026
Premium
Ratings
Buy Rating on Tvardi: Differentiated STAT3 Platform, Upcoming TTI-109/TTI-101 Catalysts, and Attractive Risk‑Reward Through 2026
1M ago
TVRD
Tvardi Therapeutics Warns Animal Welfare Rules Could Raise Costs and Delay Drug Development
Premium
Company Announcements
Tvardi Therapeutics Warns Animal Welfare Rules Could Raise Costs and Delay Drug Development
1M ago
TVRD
Tvardi Therapeutics Sets Key Deadlines for 2026 Meeting
Premium
Company Announcements
Tvardi Therapeutics Sets Key Deadlines for 2026 Meeting
2M ago
8K
TVRD
Tvardi Therapeutics: Positive Phase 2 IPF Signal and Next-Gen STAT3 Pipeline Position Shares as a Buy Ahead of 2026 Catalysts
Premium
Ratings
Tvardi Therapeutics: Positive Phase 2 IPF Signal and Next-Gen STAT3 Pipeline Position Shares as a Buy Ahead of 2026 Catalysts
3M ago
TVRD
Tvardi Therapeutics updates STAT3 fibrosis-focused clinical pipeline
Premium
Company Announcements
Tvardi Therapeutics updates STAT3 fibrosis-focused clinical pipeline
4M ago
8K
TVRD
Tvardi Therapeutics: Buy Rating Reaffirmed Amid Upcoming Catalysts and Risk-Reward Scenario
Premium
Ratings
Tvardi Therapeutics: Buy Rating Reaffirmed Amid Upcoming Catalysts and Risk-Reward Scenario
5M ago
TVRD
Tvardi Therapeutics Advances STAT3 Inhibitor Clinical Trials
Premium
Company Announcements
Tvardi Therapeutics Advances STAT3 Inhibitor Clinical Trials
6M ago
8K
TVRD
More TVRD News >

TVRD News on the Web

Analysts Offer Insights on Healthcare Companies: Achieve Life Sciences (ACHV) and Tvardi Therapeutics (TVRD)
TipRanks News
Neutral
Analysts Offer Insights on Healthcare Companies: Inhibikase Therapeutics (IKT), Tvardi Therapeutics (TVRD) and Apogee Therapeutics (APGE)
TipRanks News
Bullish
Buy Rating on Tvardi: Differentiated STAT3 Platform, Upcoming TTI-109/TTI-101 Catalysts, and Attractive Risk‑Reward Through 2026
TipRanks News
Bullish
Tvardi Therapeutics Warns Animal Welfare Rules Could Raise Costs and Delay Drug Development
TipRanks News
Bearish
Tvardi Therapeutics Narrows FY25 Loss, Prepares For Key STAT3 Clinical Readouts In 2026
rttnews
Bullish
Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and Forte Biosciences (FBRX)
TipRanks News
Neutral
Tvardi Therapeutics price target lowered to $3 from $4 at Piper Sandler
TipRanks News
Neutral
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sotera Health (SHC), Tvardi Therapeutics (TVRD) and TruBridge (TBRG)
TipRanks News
Bearish

News Score - Last 7 Days

Neutral
TVRD
Sector Average
Media Buzz
This Week1 articles
Weekly Average2.75 articles
News Sentiment
This Week50%
Sector Average70%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is TVRD’s Media Buzz Sentiment?
1 articles about TVRD were published this week. In an average week, 2.75 articles are published.
    What is TVRD’s weekly average amount of articles?
    In an average week, 2.75 articles about TVRD are published.
      What is TVRD’s News Sentiment?
      50% of articles about TVRD were positive this week, compared to its sector average of 70%.
        Healthcare Stocks that are Trending in the News
        TVTXTravere Therapeutics
        HVOOpen Orphan Plc
        PBMPsyence Biomedical
        QDELQuidelOrtho
        Showing the stocks with the most bullish news sentiment over the past week